HK Stock Market Move | SIMCERE PHARMA (02096) rose over 5% in early trading. Today, it will release its interim results, driven by significant growth in revenue from innovative drugs and business development.

SIMCERE PHARMA (02096) rose over 5% in early trading, and as of the time of writing, it is up 4.27%, priced at HKD 12.69, with a transaction volume of HKD 40.174 million. In terms of news, SIMCERE PHARMA will hold its 2026 mid-term performance briefing on August 21. The earnings announcement indicates that the company expects revenue for the first half of the year to reach between RMB 4.55 billion and RMB 4.61 billion, a year-on-year increase of approximately 26.9% to 28.6%; net profit attributable to shareholders is expected to be between RMB 810 million and RMB 860 million, a year-on-year increase of approximately 34.8% to 43.1%; and adjusted net profit attributable to shareholders is projected to be between RMB 950 million and RMB 1 billion, a year-on-year increase of approximately 46.5% to 54.2%. This is mainly attributed to the increase in revenue from innovative drugs and external licensing income. Huatai believes that amid significant industry fluctuations in the second quarter, the company has achieved an unexpectedly strong performance, demonstrating strong market demand for new products and enhanced efficiency following changes in management. Additionally, normalizing Business Development (BD) is expected to bring sustained incremental volume. It is anticipated that the company's organic business will maintain the trend indicated in its interim report forecast for the whole year, while profits will benefit from continued rapid growth in BD. The rating is maintained at "Buy."